Qurient KRX:115180KOSDAQ
큐리언트 · Korean news coverage and regulatory filings, organized.
Articles, 24h4
Articles, 7 days5
DART filings, 7 days0
Articles tracked5since Sep 11
In Q2 2026, Qurient reported revenue of ₩1.9bn, up 3.4% year on year, and an operating loss of ₩12.8bn. Qurient (큐리언트) appeared in 5 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 14 with 3 articles. It was most often mentioned alongside Orum Therapeutics, Nextbiomedical and Dentium.
Qurient quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩1.9bn | +3.4% | −₩12.8bn | −₩13.2bn |
| Q1 2026 | ₩1.9bn | +1.1% | −₩7.7bn | −₩7.9bn |
| Q4 2025 derived | ₩1.5bn | -45.8% | −₩9.3bn | −₩12.1bn |
| Q3 2025 | ₩1.7bn | -25.3% | −₩7.0bn | −₩6.6bn |
| Q2 2025 | ₩1.8bn | -7.0% | −₩6.8bn | −₩6.4bn |
| Q1 2025 | ₩1.9bn | -9.1% | −₩6.7bn | −₩6.2bn |
| Q4 2024 derived | ₩2.8bn | +17.9% | −₩7.8bn | −₩6.4bn |
| Q3 2024 | ₩2.3bn | -0.0% | −₩6.0bn | −₩5.6bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Qurient top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
